J. Scott Wolchko net worth and biography

J. Wolchko Biography and Net Worth

Mr. Wolchko is the President & Chief Executive Officer at Fate Therapeutics and is responsible for the company’s finance, administration and operations. Mr. Wolchko began his career as an investment banker with Morgan Stanley & Co., where he served for six years in the firm’s New York City and Menlo Park, California offices. As a member of Morgan Stanley’s Investment Banking Health Care Group, he assisted emerging growth companies in the health care technology sector complete capital-raising and M&A transactions. Prior to joining Fate Therapeutics, Mr. Wolchko served as the Chief Financial Officer of Bocada, Inc., where he oversaw all corporate service-related operations, and previously led Corporate Development at drugstore.com, where he was responsible for sourcing, evaluating and executing financial and business development opportunities. Mr. Wolchko holds an M.S. in biochemical engineering from the University of Virginia, and a B.S. in biomedical engineering from the University of Vermont.

What is J. Scott Wolchko's net worth?

The estimated net worth of J. Scott Wolchko is at least $2.08 million as of January 10th, 2023. Mr. Wolchko owns 385,639 shares of Fate Therapeutics stock worth more than $2,078,594 as of March 26th. This net worth approximation does not reflect any other investments that Mr. Wolchko may own. Learn More about J. Scott Wolchko's net worth.

How do I contact J. Scott Wolchko?

The corporate mailing address for Mr. Wolchko and other Fate Therapeutics executives is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. Fate Therapeutics can also be reached via phone at (858) 875-1800 and via email at [email protected] Learn More on J. Scott Wolchko's contact information.

Has J. Scott Wolchko been buying or selling shares of Fate Therapeutics?

During the last quarter, J. Scott Wolchko has sold $240,552.68 in shares of Fate Therapeutics stock. Most recently, J Scott Wolchko sold 45,907 shares of the business's stock in a transaction on Tuesday, January 10th. The shares were sold at an average price of $5.24, for a transaction totalling $240,552.68. Following the completion of the sale, the chief executive officer now directly owns 385,639 shares of the company's stock, valued at $2,020,748.36. Learn More on J. Scott Wolchko's trading history.

Who are Fate Therapeutics' active insiders?

Fate Therapeutics' insider roster includes Yu-Waye Chu (VP), Edward Dulac, III (CFO), John Mendlein (Director), Louis Petrillo (Insider), Mark Plavsic (Insider), Cindy Tahl (General Counsel), Bahram Valamehr (Insider), and J. Wolchko (CEO). Learn More on Fate Therapeutics' active insiders.

Are insiders buying or selling shares of Fate Therapeutics?

In the last year, Fate Therapeutics insiders bought shares 2 times. They purchased a total of 124,679 shares worth more than $698,138.49. In the last year, insiders at the biopharmaceutical company sold shares 13 times. They sold a total of 192,987 shares worth more than $4,360,813.19. The most recent insider tranaction occured on January, 13th when Director John Mendlein bought 36,631 shares worth more than $198,906.33. Insiders at Fate Therapeutics own 17.3% of the company. Learn More about insider trades at Fate Therapeutics.

Information on this page was last updated on 1/13/2023.

J. Scott Wolchko Insider Trading History at Fate Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/10/2023Sell45,907$5.24$240,552.68385,639View SEC Filing Icon  
7/21/2022Sell30,000$32.88$986,400.00431,546View SEC Filing Icon  
4/21/2022Sell30,000$35.00$1,050,000.00431,546View SEC Filing Icon  
1/20/2022Sell30,000$40.21$1,206,300.00View SEC Filing Icon  
1/10/2022Sell34,156$46.86$1,600,550.16View SEC Filing Icon  
11/18/2021Sell20,000$54.27$1,085,400.00View SEC Filing Icon  
10/21/2021Sell30,000$60.22$1,806,600.00View SEC Filing Icon  
8/19/2021Sell20,000$88.01$1,760,200.00View SEC Filing Icon  
7/22/2021Sell30,000$86.05$2,581,500.00View SEC Filing Icon  
4/23/2021Sell30,000$85.24$2,557,200.00423,793View SEC Filing Icon  
1/21/2021Sell30,000$103.05$3,091,500.00393,793View SEC Filing Icon  
1/11/2021Sell69,407$116.33$8,074,116.31393,065View SEC Filing Icon  
1/8/2021Sell60,820$117.10$7,122,022.00393,065View SEC Filing Icon  
1/30/2020Sell25,000$25.45$636,250.00444,969View SEC Filing Icon  
12/20/2019Sell25,000$20.17$504,250.00378,969View SEC Filing Icon  
10/15/2019Sell21,017$14.44$303,485.48View SEC Filing Icon  
5/16/2019Sell14,335$19.37$277,668.95389,216View SEC Filing Icon  
4/17/2019Sell8,541$16.17$138,107.97375,973View SEC Filing Icon  
3/21/2019Sell20,000$17.61$352,200.00View SEC Filing Icon  
4/1/2014Sell20,000$9.64$192,800.00View SEC Filing Icon  
See Full Table

J. Scott Wolchko Buying and Selling Activity at Fate Therapeutics

This chart shows J Scott Wolchko's buying and selling at Fate Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Fate Therapeutics Company Overview

Fate Therapeutics logo
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
Read More

Today's Range

Now: $5.39
Low: $5.05
High: $5.43

50 Day Range

MA: $5.89
Low: $4.88
High: $6.87

2 Week Range

Now: $5.39
Low: $4.02
High: $43.12


1,708,987 shs

Average Volume

3,514,024 shs

Market Capitalization

$529.08 million

P/E Ratio


Dividend Yield